The Latest Breaking News from Catalyst Pharmaceuticals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

This IBD 50 holding holds top notch ratings amid a market downturn.

Catalyst Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 92 the day before.

Catalyst Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.

Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.

Catalyst Pharmaceuticals doubled earnings expectations amid a strong launch for its new drug, Agamree. The biotech stock jumped Thursday.

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….